Tempus

Contact for Pricing

Share

Linkedin

Twitter

Facebook

Whatsapp

Copy Link

Tempus leverages AI-enabled precision medicine to transform patient care by making clinical and molecular data accessible and useful.

Tempus Image

Tempus Image

How Tempus can help you:

Accelerate the discovery of novel targets.
Predict the effectiveness of treatments.
Identify potentially life-saving clinical trials.
Diagnose multiple diseases earlier.
Enable more informed treatment decisions for physicians.
Assist in the development of better drugs for pharmaceutical and biotech companies.
Help patients find optimal therapy options.

Why choose Tempus: Key features

World’s largest library of clinical and molecular data.
AI-enabled operating system for data accessibility and usefulness.
FDA Breakthrough Device Designation for HLA-LOH assay.
Advanced testing, clinical trial matching, and deep research data for healthcare improvements.
AI-enabled clinical assistant Tempus One for direct patient insights.

Who should choose Tempus:

Physicians seeking informed treatment decisions.
Pharmaceutical and biotech companies targeting drug development.
Patients looking for personalized therapy options.
Researchers requiring access to comprehensive clinical and molecular data.

About Tempus

Website

https://www.tempus.com

Release Date

March 2024

Pricing

Contact for Pricing

Related fields

Categories

Health, Clinical documentation, Screening and diagnosis, Healthcare administration, Drug development

Related News

Tempus Stock: The AI Engine Powering Healthcare (NASDAQ:TEM)

Trading at 10.2x EV/Sales and 1,353x forward EV/EBITDA, Tempus requires flawless execution to justify its $7.1B valuation. Tempus AI (NASDAQ:TEM) quickly became a leader in AI-driven precision medicine, with a 35.8% growth rate, year-over-year, during Q4 2024 and issuing guidance that's bullish for 2025. Investors have cheered its tale: A genomics-data giant Pythia Research focuses on multi-bagger stocks, primarily in the technology sector. Our approach combines financial analysis, behavioral finance, psychology, social sciences, and alternative metrics to assess companies with high conviction and asymmetric risk-reward potential. By leveraging both traditional and unconventional insights, we aim to uncover breakout opportunities before they gain mainstream attention. Our multidisciplinary strategy helps us navigate market sentiment, identify emerging trends, and invest in transformative businesses poised for exponential growth. We don't just follow the market -- we anticipate where disruption will create the next big winners. Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Seeking Alpha

Sun, 20 Apr, 4:03 PM UTC

Tempus AI Rebounds with New AI-Driven Healthcare Initiatives Amid Short Seller Allegations

Tempus AI's stock surges following announcements of new AI-powered healthcare programs and analyst support, countering recent short seller criticisms.

3 Sources

Tue, 3 Jun, 8:05 AM UTC

Tempus AI Reports Strong Q2 2025 Results, Driven by AI-Powered Genomics and Data Services

Tempus AI, a leader in AI-driven precision medicine, reported impressive Q2 2025 results with revenue surging 89.6% year-over-year. The company raised its full-year outlook and is nearing adjusted EBITDA profitability, showcasing the growing impact of AI in healthcare.

7 Sources

Fri, 8 Aug, 4:04 PM UTC

Tempus AI Stock Prediction: Analysts Expect $65-$75 Price Target by 2026

The stock was supported near $55, so it has rebounded from this price in the past. If it does, the stock may start climbing once more. If it dips under $55, it may encounter additional selling. fuses genomics, machine learning, and clinical data to assist physicians in making superior treatment choices. The company has a broad footprint in other areas of healthcare, such as oncology, cardiology, and radiology. It works in more than 30 countries, partnering with hospitals, pharmaceutical firms, and research hubs. The key benefit is its reach to data from more than 50% of all US oncology clinics. This provides Tempus's AI with a large sample to learn from and fine-tune diagnoses. It has partnered with global companies like AstraZeneca and formed joint ventures in markets such as Japan. These partnerships help extend its worldwide reach and strengthen its technology. While still unprofitable, Tempus is getting better with its financials. Prices for genetic sequencing are falling, which will aid margins as time goes on. While the company's R&D spend is still high, that's part of its multi-pronged plan to be a leader in AI-powered healthcare.

Analytics Insight

Mon, 14 Jul, 12:23 PM UTC

Tempus AI, Inc. acquired Paige.AI, Inc. in a transaction valued at $81.2 million.

Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Companyâs product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The Company's AI applications are focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. Its primary product of AI applications is Next, an AI platform that leverages machine learning to apply an intelligent layer onto routinely generated data to proactively identify and minimize care gaps for oncology and cardiology patients.

Market Screener

Fri, 22 Aug, 8:09 PM UTC

Similar products

BenevolentAI

BenevolentAI utilizes AI to accelerate drug discovery, enhancing scientific innovation and the likelihood of discovering successful drugs.

Contact for Pricing

Paige.AI

Paige is transforming the way pathologists work through a comprehensive digital pathology platform and generative AI applications.

Contact for Pricing

MDClone

MDClone is an AI-powered tool designed to democratize healthcare data, allowing organizations to utilize their in-house data to improve patient outcomes.

Freemium

Unlearn

Unlearn is a digital platform that uses artificial intelligence to create digital clones of human physiological responses, helping in drug development and clinical trials.

Contact for Pricing

PharmaTrace

PharmaTrace provides AI-powered digital solutions for chronic disease management, focusing on enhancing patient outcomes and preventing medical complications.

Contact for Pricing

Your Daily Dose of Curated AI News

Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Spend less time searching for the latest in AI and get straight to action.

The Outpost

News

About

© 2025 Triveous Technologies Private Limited